PDS Biotechnology (NASDAQ:PDSB) inks an agreement with Farmacore Biotechnology to co-develop a COVID-19 vaccine.
The candidate, dubbed Versamune-CoV-2FC, combines PDS’s Versamune platform with Farmacore’s recombinant SARS-CoV-2 protein.
Under the terms of the deal, Farmacore retains
commercialization rights in Latin America while revenue there will be
shared. PDS retains the right of first refusal for commercialization
rights ex-Latin America. Specific financial terms are not disclosed.
PDS is in talks with governmental and non-governmental agencies about additional funding for the vaccine.
A Phase 1 study in Brazil is next up.
https://seekingalpha.com/news/3583779-pds-biotech-teams-up-farmacore-on-covidminus-19-vaccine
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.